(VIANEWS) – TG Therapeutics (TGTX), Adobe (ADBE), Lifeway Foods (LWAY) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. TG Therapeutics (TGTX)
67.5% sales growth and 43.93% return on equity
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.
Earnings Per Share
As for profitability, TG Therapeutics has a trailing twelve months EPS of $0.3.
PE Ratio
TG Therapeutics has a trailing twelve months price to earnings ratio of 60. Meaning, the purchaser of the share is investing $60 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 43.93%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 85.3% and a drop 101.4% for the next.
Sales Growth
TG Therapeutics’s sales growth is 277.6% for the present quarter and 67.5% for the next.
Yearly Top and Bottom Value
TG Therapeutics’s stock is valued at $18.00 at 20:22 EST, way under its 52-week high of $26.95 and way above its 52-week low of $6.46.
Revenue Growth
Year-on-year quarterly revenue growth grew by 713.5%, now sitting on 289.33M for the twelve trailing months.
2. Adobe (ADBE)
20.5% sales growth and 34.22% return on equity
Adobe Inc., together with its subsidiaries, operates as a diversified software company worldwide. It operates through three segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products, services, and solutions that enable individuals, teams, and enterprises to create, publish, and promote content; and Document Cloud, a unified cloud-based document services platform. Its flagship product is Creative Cloud, a subscription service that allows members to access its creative products. This segment serves content creators, students, workers, marketers, educators, enthusiasts, and communicators. The Digital Experience segment provides an integrated platform and set of applications and services that enable brands and businesses to create, manage, execute, measure, monetize, and optimize customer experiences from analytics to commerce. This segment serves marketers, advertisers, agencies, publishers, merchandisers, merchants, web analysts, data scientists, developers, and executives across the C-suite. The Publishing and Advertising segment offers products and services, such as e-learning solutions, technical document publishing, web conferencing, document and forms platform, web application development, and high-end printing, as well as Advertising Cloud offerings. It also provides consulting, technical support, and learning services. The company offers its products and services directly to enterprise customers through its sales force and local field offices, as well as to end users through app stores and through its website at adobe.com. It also distributes products and services through distributors, value-added resellers, systems integrators, software vendors and developers, retailers, and original equipment manufacturers. The company was formerly known as Adobe Systems Incorporated and changed its name to Adobe Inc. in October 2018. Adobe Inc. was founded in 1982 and is headquartered in San Jose, California.
Earnings Per Share
As for profitability, Adobe has a trailing twelve months EPS of $10.46.
PE Ratio
Adobe has a trailing twelve months price to earnings ratio of 45.32. Meaning, the purchaser of the share is investing $45.32 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.22%.
Previous days news about Adobe(ADBE)
- According to Zacks on Monday, 1 July, "Recently, it collaborated with Adobe Inc. to aid clients tap the power of Adobe Experience Cloud through its new Adobe Studio."
3. Lifeway Foods (LWAY)
14.9% sales growth and 23.09% return on equity
Lifeway Foods, Inc. produces and markets probiotic-based products in the United States and internationally. Its primary product is drinkable kefir, a cultured dairy product in various organic and non-organic sizes, flavors, and types. The company also offers European-style soft cheeses; cream and other products; ProBugs, a line of kefir products designed for children; drinkable yogurt; and fresh made butter and sour cream. It sells its products under the Lifeway, Glen Oaks Farms, and Fresh Made brand names, as well as under private labels on behalf of customers primarily through direct sales force, brokers, and distributors. The company was incorporated in 1986 and is based in Morton Grove, Illinois.
Earnings Per Share
As for profitability, Lifeway Foods has a trailing twelve months EPS of $0.85.
PE Ratio
Lifeway Foods has a trailing twelve months price to earnings ratio of 14.55. Meaning, the purchaser of the share is investing $14.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.09%.
Yearly Top and Bottom Value
Lifeway Foods’s stock is valued at $12.37 at 20:22 EST, way under its 52-week high of $28.61 and way above its 52-week low of $5.77.
4. Iron Mountain Incorporated (IRM)
9.2% sales growth and 47.37% return on equity
Iron Mountain Incorporated (NYSE: IRM), founded in 1951, is the global leader for storage and information management services. Trusted by more than 225,000 organizations around the world, and with a real estate network of more than 90 million square feet across more than 1,480 facilities in approximately 50 countries, Iron Mountain stores and protects billions of valued assets, including critical business information, highly sensitive data, and cultural and historical artifacts. Providing solutions that include secure records storage, information management, digital transformation, secure destruction, as well as data centers, cloud services and art storage and logistics, Iron Mountain helps customers lower cost and risk, comply with regulations, recover from disaster, and enable a more digital way of working.
Earnings Per Share
As for profitability, Iron Mountain Incorporated has a trailing twelve months EPS of $0.66.
PE Ratio
Iron Mountain Incorporated has a trailing twelve months price to earnings ratio of 133.36. Meaning, the purchaser of the share is investing $133.36 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 47.37%.
5. WillScot Mobile Mini Holdings Corp. (WSC)
7% sales growth and 22.32% return on equity
WillScot Mobile Mini Holdings Corp. provides modular space and portable storage solutions in the United States, Canada, Mexico, and the United Kingdom. The company leases various office space and storage solutions for temporary applications across a customer base in the commercial and industrial, construction, retail, education, health care, government, transportation, security, and energy sectors. . It operates a fleet of over 350,000 portable offices and storage containers. The company is headquartered in Phoenix, Arizona.
Earnings Per Share
As for profitability, WillScot Mobile Mini Holdings Corp. has a trailing twelve months EPS of $1.62.
PE Ratio
WillScot Mobile Mini Holdings Corp. has a trailing twelve months price to earnings ratio of 23.23. Meaning, the purchaser of the share is investing $23.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.32%.
Moving Average
WillScot Mobile Mini Holdings Corp.’s worth is below its 50-day moving average of $38.84 and way below its 200-day moving average of $42.10.
6. ICON plc (ICLR)
6.5% sales growth and 7.55% return on equity
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; and clinical research services, including biostatistics, clinical operations, clinical supplies management, covid-19, data management, decentralized & hybrid clinical solutions, endpoint adjudication services, interactive response technologies, investigator payments, medical affairs, medical writing and publishing, pharmacovigilance, and site and patient solutions. The company also provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. In addition, it offers commercial positioning, early phase, language, medical imaging, and strategic solutions, as well as clinical trial management, consulting, and contract staffing services. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, ICON plc has a trailing twelve months EPS of $8.23.
PE Ratio
ICON plc has a trailing twelve months price to earnings ratio of 38.73. Meaning, the purchaser of the share is investing $38.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.55%.
Yearly Top and Bottom Value
ICON plc’s stock is valued at $318.78 at 20:22 EST, below its 52-week high of $344.77 and way higher than its 52-week low of $221.20.
